BridgeBio Pharma (BBIO) Profit After Tax (2019 - 2025)
Historic Profit After Tax for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to -$184.9 million.
- BridgeBio Pharma's Profit After Tax fell 1259.21% to -$184.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$805.7 million, marking a year-over-year decrease of 8053.27%. This contributed to the annual value of -$543.3 million for FY2024, which is 1682.42% up from last year.
- According to the latest figures from Q3 2025, BridgeBio Pharma's Profit After Tax is -$184.9 million, which was down 1259.21% from -$183.8 million recorded in Q2 2025.
- In the past 5 years, BridgeBio Pharma's Profit After Tax registered a high of -$2.6 million during Q2 2022, and its lowest value of -$267.4 million during Q4 2024.
- In the last 5 years, BridgeBio Pharma's Profit After Tax had a median value of -$161.0 million in 2021 and averaged -$147.7 million.
- In the last 5 years, BridgeBio Pharma's Profit After Tax skyrocketed by 9749.3% in 2022 and then tumbled by 617991.4% in 2023.
- Quarter analysis of 5 years shows BridgeBio Pharma's Profit After Tax stood at -$152.3 million in 2021, then increased by 7.69% to -$140.6 million in 2022, then fell by 21.17% to -$170.3 million in 2023, then plummeted by 56.98% to -$267.4 million in 2024, then surged by 30.84% to -$184.9 million in 2025.
- Its Profit After Tax was -$184.9 million in Q3 2025, compared to -$183.8 million in Q2 2025 and -$169.6 million in Q1 2025.